FDA Brief

Warning letters Drugs

FDA warning letter to

BioMylz Pvt. Ltd.

High riskIssued Jul 13Posted Jul 21Center for Drug Evaluation and Research (CDER)

FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.

What happened

FDA inspected BioMylz’s Bengaluru, India drug manufacturing facility from February 4 to 9, 2026, and reviewed its drug listings in FDA’s electronic listing system. Investigators found original CGMP records in a garbage bag, missing original laboratory data, uncontrolled logbooks, inadequate process and cleaning validation after scale-up, and no testing of the topical psoriasis cream for objectionable microorganisms. FDA also found the listings for Soraresal Cream and Equate Medicated Vaporizing Steam Liquid omitted required manufacturing establishments that were not registered with FDA.

What FDA found

  1. The quality control unit did not ensure drug products met CGMP and specifications, and original CGMP records were found in a garbage bag while original laboratory data were missing.

    21 CFR 211.22
  2. Laboratory logbooks had unnumbered pages, lacked reconciliation, and were not completed contemporaneously, including entries first made in pencil and later overwritten in ink.

    21 CFR 211.22
  3. The company did not adequately validate its manufacturing process after commercial scale-up and did not document critical process parameters in batch records.

    21 CFR 211.100(a) and 211.100(b)
  4. Cleaning procedures were not shown effective for removing API residue and controlling microbial contamination on shared equipment after scale-up.

    21 CFR 211.100(a) and 211.100(b)
  5. The topical psoriasis cream was not tested for objectionable microorganisms such as Staphylococcus aureus and Pseudomonas aeruginosa.

    21 CFR 211.160(b)
  6. Drug listings for Soraresal Cream and Equate Medicated Vaporizing Steam Liquid omitted required manufacturing establishments, including testing laboratories not registered with FDA, making the drugs misbranded.

    FD&C Act sections 510(j) and 502(o); 21 CFR 207.49(a)(12)

What FDA wants

FDA tells BioMylz to respond in writing within 15 working days with corrective actions and supporting documentation, including comprehensive data-integrity and validation investigations, risk assessments, and corrective action and preventive action plans. FDA also strongly recommends an independent qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC drugs from this contract manufacturer
  • U.S. importers and distributors of Soraresal Cream or Equate Medicated Vaporizing Steam Liquid
  • contract manufacturers with shared equipment and data-integrity risks

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk